Percuros B.V.
Percuros B.V., a Dutch biotech company, was founded by Alan Chan in 2005 based on bone biomarkers for treatment of osteoporosis. In addition David Galas and Jeff van Ness from the Keck Graduate Institute (KGI) also came on board as co-founders and brought along their experience as early pioneers of isothermal PCR and protein-based algorithms. A KGI spin-off, Zuyder Inc., was subsequently incorporated into Percuros. The Company graduated towards developing biomarker assays for immunotherapy and oncology and to this day it specialises in designing both in vivo and in vitro assays for clients.
The company has a wealth of experience, with 11 R&D employees on board, who work on technologies that span isothermal PCR, gene expression assays, in vivo and in vitro bioluminescence and fluorescence imaging, biosensors and nanoparticles. Percuros has a product portfolio of cell-based assays and specialised equipment dedicated to optical imaging using spatiotemporal tracking of cells in vivo. The company possesses enabling tools (optical imaging and gene reporter assays) to validate efficacy of drugs, cell therapy and image-guided surgery.

Staff Expertise
  • Dr Alan Chan is a molecular imaging specialist who has worked on in vivo time domain imaging (fluorescence lifetime) and readouts to establish spatiotemporal reaction kinetics. He is supervising and mentoring students and young scientists on a daily basis and is committed to do so also for ESR11. In addition, Dr Chan is fully committed to act as PhD CS for ESRs15 and 17 and help training and mentoring 2, 16 and 20, which are trained in the scope of this ITN as outlined in the respective sections.
  • Dr Karien de Rooij specialises in skeletal biology, assay development, FLI/SPECT/MRI and μCT imaging and will guide ESR11 on a daily basis in the laboratory. Dr. de Rooij will also be involved during the SECs that are hosted by PERC (the reasoning for those SECs is outlined in Table 19). As there are 11 full time FTEs employed within the R&D group of PERC, those will also support this ITN project, i.e, all staff members will support the SECs utilizing their respective skills such as targeting probes for surgery, to validate pathways using molecular imaging techniques on in vivo syngeneic mice models, to test out the immune regulatory gene signatures on in vivo syngeneic mice models, to work on PLGA structural modifications, to test and optimise the transgenic mouse model for dual coloured readouts, to look at specificity of the NPs to their targets, PERC is also committed to contribute towards the training as described in TPs 1-4, specifically utilizing its experience for workshop 4 (transferable skills training 4.1 and 4.2), i.e. focusing on IP, career planning and workshop 5 (transferable skills 5.1 and 5.2), i.e. entrepreneurship and e-learning.

Key facilities and infrastructure
  • Percuros has animal housing and in vivo facilities including state-of-art in vivo molecular imaging systems.
  • Several transgenic mice and xenotransplant models are present in these facilities.
  • The labs are equipped for confocal microscopy, immunohistochemistry and cell-based readers.
  • Those elements will be utilized for WP5 (in collaboration with LUMC) as well as WP3

Previous involvement in Research and Training Programmes
  • 2008 - 2011 European Union FP6 funded program for osteoporosis,
  • 2008 - 2011 SenterNovem (IOP Genomics),
  • 2008 - 2013 CTMM (Dutch) funded program ‘DeCoDe’ for colorectal cancer research,
  • 2008 - 2013 CTMM (Dutch) funded program ‘PREDICCt’ for diabetes research,
  • 2009 - 2014 BMM funded program ‘OAControl’ for osteoarthritis research,
  • 2010 - 2012 Pieken in de Delta funded program ‘Perfectos’ for development of biomaterials for bone repair, 2010 - 2013 EUROSTARS program, PORAC, for osteoarthritis research and assay development,
  • 2010 - 2013 International Innoveren project (DETTL) for a South Korean and Dutch collaboration on nanoparticles and imaging Partners,
  • 2010 - 2014 Dutch-funded photodynamic therapy project, IMPAC,
  • 2012 - 2014 Dutch-funded TIPharma project on immunotherapy and imaging. Dr. Chan has already supervised 3 PhD students in the past as is fully commited to provide the same quality training to EST11.

Current Involvement in Research and Training Programmes
  • 2010 - 2015 CTMM (Dutch) funded program ‘Cancer Vaccine Tracking’ for vaccine imaging,
  • 2012 - 2015 NIRM project - Model systems and technologies for skeletal regeneration,
  • 2013 - 2017 Co-ordinator of the EU Marie Curie IAPP project, BRAINPATH)
  • 2014 - 2017 EU Marie Curie ITN project, TARGETCARE,
  • 2014 - 2017 EU Marie Curie project, ELECTOR,
  • 2014 - 2018 Co-ordinator of the EU Marie Curie RISE project, PRISAR

  • Hollestelle A. et al. Breast Cancer Res Treat. (2013)
  • Xie B.W. et al. Cell Death Dis. (2013)
  • van Driel P.B. et al. Int J Cancer. (2014)
  • Xie B.W. et al. PLoS One. (2012)
  • Chan A.B. et al. Curr Cardiovasc Imaging Rep. (2012)

Overview of all participants ...